Albuterol Delivered via Metered-Dose Inhaler With Spacer for Outpatient Treatment of Young Children With Wheezing
- 1 February 1994
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 148 (2) , 189-194
- https://doi.org/10.1001/archpedi.1994.02170020075013
Abstract
Objective: To determine the efficacy of albuterol delivered via metered-dose inhaler with spacer for the treatment of wheezing infants. Design and Setting: Double-blind, prospective, placebocontrolled, clinical crossover trial undertaken at the emergency department of a university-affiliated children's hospital. Participants: Forty-two patients aged 1 to 18 months presenting to the emergency department with wheezing. Intervention: Subjects were randomly assigned to one of two blinded treatment groups. Group 1 received two albuterol treatments followed by two placebo treatments. Group 2 received two placebo treatments followed by two albuterol treatments. Each treatment consisted of two puffs from a metered-dose inhaler with spacer at 20-minute intervals. Measurements/Main Results: On enrollment and 20 minutes after each treatment, a clinical assessment was made by the principal investigator, which included heart rate, respiratory rate, pulse oximetry, wheezing score (0 to 3), and retraction score (0 to 3). Both treatment groups had statistically significant improvement in mean wheezing score associated with albuterol therapy (P<.05 using Dunnett's t test). Mean retraction score improved over time in both groups only during drug therapy. However, the improvement of only group 2 reached statistical significance (P<.05 using Dunnett's t test). Scores were then classified as "improved" and "not improved" for analysis with McNemar's test. Group 2 had a statistically significant proportion of patients with improved retraction score related to albuterol therapy. The remaining dichotomized results, while not achieving statistical significance, showed a trend in the direction expected from a beneficial drug effect. Conclusions: Albuterol delivered by metered-dose inhaler with spacer to wheezing infants aged 1 to 18 months reduces the severity of wheezing and retractions. (Arch Pediatr Adolesc Med. 1994;148:189-194)Keywords
This publication has 24 references indexed in Scilit:
- The use of nebulized albuterol in wheezing infantsPediatric Emergency Care, 1992
- The Efficacy of Nebulized Metaproterenol in Wheezing Infants and Young ChildrenArchives of Pediatrics & Adolescent Medicine, 1992
- Randomized trial of salbutamol in acute bronchiolitisThe Journal of Pediatrics, 1991
- Do wheezy infants recovering from bronchiolitis respond to inhaled salbutamol?Pediatric Pulmonology, 1991
- Bronchial reactivity in infants in acute respiratory failure with viral bronchiolitisPediatric Pulmonology, 1989
- Effect of Salbutamol on Respiratory Mechanics in BronchiolitisPediatric Research, 1987
- Bronchodilator response during acute viral bronchiolitis in infancyPediatric Pulmonology, 1985
- Alpha and beta adrenergic stimulants in bronchiolitis and wheezy bronchitis in children under 18 months of age.Archives of Disease in Childhood, 1978
- Effect of bronchodilators on respiratory resistance in infants and young children with bronchiolitis and wheezy bronchitis.Archives of Disease in Childhood, 1975
- Effect of salbutamol in infants with wheezy bronchitis.Archives of Disease in Childhood, 1975